Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

CANCER CELL

CELL PRESS

1. Belgian Federal Government through Sciensano
2. University of Liege through Credits Sectoriels de Recherche en Sciences de la Sante (FSR 2021)
3. Research Foundation -Flanders [FWO G0G4220N]
4. KU Leuven